This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
FRAMINGHAM, Mass. and
July 30, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended
June 30, 2012, at
5:00 p.m. U.S. Eastern Daylight Time on
Tuesday, August 7, 2012 (being
7:00 a.m. Australian Eastern Standard Time, on
August 8, 2012). The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the second quarter and business outlook. The call may be accessed by dialing 1-877-941-4775 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-480-629-9761.
A live webcast of the call will also be available at the Company's website (
www.heartware.com) by selecting "HeartWare Second Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.
A copy of the news release announcing results and related information will be available on the Company's website,
About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare
® Ventricular Assist System features the HVAD
® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System has received CE Marking in the European Union and TGA approval in
Australia. The device is currently the subject of
United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol. For additional information, please visit the Company's website at